RMTG (Regenerative Medical Technology Group) Accounts Payable: $0.21 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerative Medical Technology Group Accounts Payable?

Regenerative Medical Technology Group RMTG +26.42% Accounts Payable is $0.21 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Regenerative Medical Technology Group's Accounts Payable for the quarter that ended in Mar. 2026 was $0.21 Mil.

Regenerative Medical Technology Group's quarterly Accounts Payable increased from Sep. 2025 ($0.34 Mil) to Dec. 2025 ($0.35 Mil) but then declined from Dec. 2025 ($0.35 Mil) to Mar. 2026 ($0.21 Mil).

Regenerative Medical Technology Group's annual Accounts Payable increased from Dec. 2023 ($0.42 Mil) to Dec. 2024 ($0.56 Mil) but then declined from Dec. 2024 ($0.56 Mil) to Dec. 2025 ($0.35 Mil).

Regenerative Medical Technology Group Accounts Payable Related Terms

Regenerative Medical Technology Group Accounts Payable Historical Data

* Premium members only.

The historical data trend for Regenerative Medical Technology Group's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerative Medical Technology Group Accounts Payable Chart

Regenerative Medical Technology Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only 0.18 0.25 0.42 0.56 0.35

Regenerative Medical Technology Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.18 0.34 0.35 0.21

Regenerative Medical Technology Group Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.21 Mil mean?
Regenerative Medical Technology Group (RMTG) has a Accounts Payable of $0.21 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Regenerative Medical Technology Group and its competitors.
Is Regenerative Medical Technology Group's Accounts Payable too high?
Regenerative Medical Technology Group's current Accounts Payable is $0.21 Mil.
How does Regenerative Medical Technology Group's Accounts Payable compare to PTIX and CERO?
Regenerative Medical Technology Group's Accounts Payable of $0.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Regenerative Medical Technology Group and its competitors. Regenerative Medical Technology Group's current Accounts Payable is $0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.09 — trading 48.3% above its estimated fair value. The current Accounts Payable is $0.21 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Accounts Payable is $0.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerative Medical Technology Group Business Description

Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.